Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 70.11% | 16.30% | 90.97% | -270.52% | 24.27% |
| Total Depreciation and Amortization | -2.00% | 66.50% | 70.54% | 107.75% | 83.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -154.26% | -63.03% | -586.75% | 1,692.70% | -194.16% |
| Change in Net Operating Assets | -104.02% | 200.24% | -852.63% | -339.90% | 355.29% |
| Cash from Operations | -13.73% | -13.62% | -87.80% | -86.00% | -29.47% |
| Capital Expenditure | 77.02% | 100.00% | -- | -- | -126.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 77.02% | 100.00% | -- | -- | -126.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -21.94% | -- | -- | -95.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -21.94% | -- | -- | -95.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.49% | -39.32% | -88.09% | 524.10% | -552.74% |